Cordis Launches Mynx Control Vascular Closure Device
November 2, 2018—Cordis, a Cardinal Health company, announced the United States launch of the Mynx Control vascular closure device (VCD). The device integrates active extravascular sealing and resorbability properties with a next-generation delivery system to maximize predictability, safety, and ease of use in sealing 5- to 7-F femoral arterial access sites. Vascular closure devices reduce time to hemostasis and ambulation in patients who have undergone diagnostic or interventional procedures.
According to Cordis, the Mynx Control VCD features a next-generation deployment system that is designed for predictable deployment and ease of use. It will be available in 5- and 6/7-F sizes.
The new system includes sheath catch that is compatible with the procedural sheath, tension indicator that provides visual confirmation of device position for proper sealant deployment, and an ergonomic handle with a two-button deployment design to simplify procedural steps.
The Mynx Control, which leverages the Cordis MynxGrip VCD technology, utilizes a dual-mode active-sealing mechanism that allows the sealant to interlock with the contours of the arterial wall, expanding to fill the tissue tract and create a matrix structure for clot formation. All closure components are resorbed within 30 days. The Mynx technology has been clinically proven to reduce surgical complications, expedite recovery, shorten hospital stays, and increase patient comfort, stated the company.